A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

NCT04333706 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Breast
Metastatic
Triple Negative
Cancer
Disseminated Tumor Cell

Interventions

DRUG: Capecitabine
COMBINATION_PRODUCT: Sarilumab 150mg or 200 mg plus Capecitabine
COMBINATION_PRODUCT: Sarilumab 150mg plus Capecitabine

Sponsor

University of Southern California

Collaborators

[object Object]